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Abstract
Background Differences in estrogen (ER) and proges-
terone (PR) expression between invasive lobular carcinoma
(ILC) and invasive ductal carcinoma (IDC) could be an
underlying reason for the difference in chemo-sensitivity
and response to hormonal therapy between ILC and IDC.
The aim of this study was to investigate the differences in
ER and PR expression levels between postmenopausal
patients with hormonal receptor-positive ILC and IDC.
Methods We included all ER and/or PR receptor-positive
ILC and IDC, diagnosed between January 2011 and
December 2013 from the population-based Netherlands
Cancer Registry. A semi-quantitative classification was
used to analyze differences in ER/PR expression, which
consisted of three ER expression classes: 10–69, 70–89,
and C90%. Differences in ER and PR expression levels
between IDC and ILC were analyzed according to age
group, tumor size, axillary nodal status, grade, and HER2
status.
Results In total, 26,339 ER and/or PR-positive breast
cancers were included in the study, of which 17% were ILC
and 83% IDC. In patients with IDC, 86% of the tumors
showed an ER expression level of 90% or more, compared
to 84% in those with ILC. In both IDC and ILC a PR
expression level of 90% or more was observed in 54% of
the tumors. In postmenopausal patients aged 50–69 years
no significant differences could be observed in ER and PR
expression levels between ILC and IDC.
Conclusion Patients with ER and PR-positive ILC and
IDC have similar quantitative ER and PR expression pro-
files, implicating that ER/PR expression is unlikely to be a
confounding factor in studies concerning chemo-sensitivity
of ILC and IDC.
Keywords Invasive lobular carcinoma  Invasive ductal
carcinoma  Estrogen receptor  Progesterone receptor
Introduction
Next to invasive ductal carcinoma (IDC), invasive lobular
carcinoma (ILC) is the second most common type of breast
cancer, representing approximately 15% of all breast
tumors. ILC is unique in its biological and clinical
behavior, with a lower E-cadherin expression and a greater
likelihood of being hormone receptor positive than IDC.
Local control and survival is reported to be similar in
patients with ILC and IDC [1, 2].
In modern treatment guidelines, no discrimination is
made between ILC and IDC regarding use of systemic
treatment [3], even though previous studies have shown an
inferior response of estrogen (ER) and/or progesterone
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(PR)-positive ILC to neoadjuvant chemotherapy, compared
to ER/PR-positive IDC. This difference is most pro-
nounced when looking at the rates of pathological complete
response. Reported proportions of patients with a patho-
logical complete response range from 0 to 5% for patients
with ER/PR-positive ILC, compared to 6 to 20% for those
with ER/PR-positive IDC [4–6]. In contrast, significantly
higher rates of pathological complete response, ranging up
to almost 18%, are seen in the small portion of patients
with ER/PR negative and poorly differentiated ILC, sug-
gesting an important role for hormonal receptor status in
this histological subgroup [7]. Furthermore, studies from
our group showed that adjuvant chemotherapy seems to
confer no additional beneficial effect to hormonal therapy
in postmenopausal patients with primary non-metastatic
ILC. In contrast, patients with IDC showed a relative risk
reduction in mortality of about 17% with the addition of
chemotherapy to hormonal treatment in the adjuvant set-
ting [8, 9].
An important limitation in studies comparing the effect
of adjuvant treatment in ILC and IDC is the lack of data
concerning quantitative ER and PR levels, which could
possibly be a confounding factor when interpreting these
results. Quantitative data about the ER/PR expression in
these patients could elucidate the question whether it is a
higher ER/PR level or another intracellular signaling
pathway related to histology that explains the lower
chemo-sensitivity or higher response to endocrine therapy
in ILC, compared to IDC. Therefore, we questioned if a
difference exists in the quantitative ER and PR status of
patients with ILC or IDC.
Methods
Patients
All female patients with ER and/or PR receptor-positive
ILC or IDC diagnosed between January 2011 and
December 2013 were selected from the population-based
Netherlands Cancer Registry. According to Dutch guide-
lines, breast tumors were called ER or PR positive when
the expression level was 10% or higher.
The registry records data on all patients with a new
diagnosis of in situ and invasive tumors in the Nether-
lands. Trained registry managers prospectively collected
data from medical records after notification, which are
mainly obtained from the automated pathology archive
(PALGA). Other sources used were the National Registry
of Hospital Discharge Diagnoses and the databases of the
radiotherapy departments. Data about patient, tumor, and
treatment characteristics were collected from patient
hospital files.
In total, 46,022 invasive breast cancers were diagnosed
in the years 2011–2013. From these 46,022 breast cancers,
we excluded 2271 tumors who were diagnosed together
with distant metastatic disease and 3225 tumors who were
not treated with surgery. From the remaining 40,526 breast
cancers we excluded those for which neoadjuvant
chemotherapy was used (n = 4789) and selected only breast
cancers of either lobular or ductal histology, leaving a total
33,441 breast cancers.
Statistical analyses
For each breast tumor, the percentage of ER and PR
expression was derived from the database. The primary
study endpoint of the study is the distribution of ER and PR
expression levels in patients with hormone receptor-posi-
tive ILC, as compared with hormone receptor-positive
IDC. To analyze differences in ER and PR expression
levels between ILC and IDC, a semi-quantitative classifi-
cation was used, which consisted of three ER expression
classes: 10–69, 70–89 and [90%. These analyses were
stratified according to age group, postoperative nodal sta-
tus, postoperative tumor size, tumor grade, and HER2
status. Differences in patient characteristics between
patients with IDC or ILC were calculated using the v2 test.
Results
Characteristics
ER or PR status was missing for 509 (1.5%) of the 33,441
tumors selected for the study. A positive ER status was
observed in 26,118 tumors (78,1%), and a positive PRstatus in
21,348 tumors (63,8%). In 6645 tumors (10.9%), the ER and
the PR status were both negative, and in 21,179 tumors
(63.3%) both receptors were positive. In total, 26,339 ER or
PR-positive breast cancers were included in the study, of
which 17% were ILC and 83% IDC. Characteristics of these
tumors are shown inTable 1.Age at diagnosis of patientswith
ILC was somewhat higher than age at diagnosis of those with
IDC.Although IDCswere smaller, theyweremore likely to be
poorly differentiated (grade 3), compared to ILCs. IDCs were
more often HER2-positive, compared to ILCs.
ER expression in ILC and IDC
The distribution of the ER expression level in ILC and IDC
is presented in Fig. 1, and the expression levels in different
subgroups is shown in Table 2. In patients aged
50–69 years, the proportion of patients with a high ER
expression level (C90%) was somewhat smaller in those
with ILC than in those with IDC (84 vs. 87%, respectively).
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Also in patients aged 70 years or older, the group with high
ER expression levels was somewhat smaller in those with
ILC, compared to those with IDC (88 vs. 91%, respec-
tively). In patients with small tumors, well-differentiated
tumors, HER2-positive tumors, or a negative axillary
lymph node status, the ER expression level was higher in
IDC than in ILC. The ER expression level was higher in
patients with ILC than in patients with IDC for those with
larger tumors and poorly differentiated tumors.
PR expression in ILC and IDC
The distribution of the PR expression level in ILC and IDC
is presented in Fig. 2, and Table 3 shows the PR expression
levels in different subgroups. In patients with ILC, the
proportion with a high PR expression level (C90%) was
54%, compared to a similar 54% in those with IDC. In
patients aged\50 years, the proportion of patients with a
high PR expression level (C90%) was somewhat higher in
those with ILC than in those with IDC (63 vs. 58%,
respectively). In patients aged 70 years or older, the group
with a high PR level was smaller in those with ILC,
compared to those with IDC (49 vs. 54%, respectively). No
remarkable differences in PR levels were observed
between ILC and IDC in stratified analyses according to
tumor size and axillary nodal status. The PR expression
level was higher in poorly differentiated ILC, compared to
poorly differentiated IDC (51 vs. 41%, respectively).
Discussion
In the present study, performed with prospectively col-
lected data from the Netherlands Cancer Registry, statis-
tically significant differences in ER and PR expression
levels were observed between patients with ILC and IDC.
However, the absolute differences were very small and are
unlikely to be of clinical relevance. In ER-positive breast
cancer patients, more than 80% showed an expression level
of more than 90%. Especially in postmenopausal patients
aged 50-69 years with ER-positive breast cancer, no sig-
nificant differences could be observed in ER expression
levels between ILC and IDC patients. Furthermore, the
differences in PR expression levels between ILC and IDC
were even smaller, compared to ER levels. We are not
aware of previous studies reporting on highly detailed ER/
PR expression levels of ILC and IDC in a large dataset of
more than 25,000 patients.
The primary reason to perform the present study was to
determine if differences in quantitative ER/PR expression
between ILC and IDC could be an important limitation for
the interpretation of the results of our previously published
study [9]. In that study, we found that adding chemother-
apy to hormonal treatment did not improve the overall
survival of patients with ILC, in contrast to those with IDC,
who clearly benefited from the use of chemotherapy.
According to criticasters, this result could partially be
explained by the better response of ILC to hormonal
therapy due to higher ER expression levels, compared to
patients with IDC [10]. In the present study, we proved that
among patients with ER-positive breast cancer, there were
no clinically relevant differences with respect to ER/PR
expression levels. This conclusion suggests that it is the
lobular histology itself that relates to the lower chemo-
sensitivity compared to the ductal counterpart.
The discussion about the reduced chemo-sensitivity of
ILC is ongoing for several years now. The added value of
(neo)adjuvant chemotherapy in ER-positive ILC was
already questioned in reviews by Katz et al. and Purusho-
tham et al. [11, 12]. In several randomized neoadjuvant trials
and population-based case series, patients with ILC were
shown to have a significantly lower pathological complete
response percentages, compared to patients with IDC [4–6].
Also in a recent, pooled analysis of nine neoadjuvant trials
including 1052 patients with ILC, a low percentage of
Table 1 General characteristics of estrogen receptor or progesterone
receptor-positive invasive lobular (ILC) or invasive ductal (IDC)
breast cancers, diagnosed between 2011–2013
Characteristic ILC (n = 4513) IDC (n = 21,826) P
No. % No. %
Age at diagnosis (years)
\50 675 (15) 4050 (19) \0.0001
50–69 2512 (56) 12,348 (57)
C70 1326 (29) 5428 (25)
Tumor size (cm)
\1 691 (15) 5180 (23) \0.0001
1–2 1710 (38) 10,438 (48)
[2 2049 (45) 6006 (28)
Unknown 63 (1) 202 (1)
Axillary nodal status
Negative 2840 (63) 14,418 (66) 0.0002
Positive 1600 (35) 7056 (32)
Unknown 73 (2) 352 (2)
Grade
1 773 (17) 6364 (29) \0.0001
2 3127 (69) 9883 (45)
3 416 (9) 4970 (23)
Unknown 197 (4) 609 (3)
HER2 status
Negative 4255 (94) 19,229 (88) \0.0001
Positive 184 (4) 2255 (10)
Unknown 74 (2) 342 (2)
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pathologic complete response was observed. However, the
lower response rate did not translate into a poorer long-term
outcome. Based on the lower response rates, it was recom-
mended in this study that the use of neoadjuvant
chemotherapy in patients with ILC should be restricted to the
small proportion with ER-negative disease [7]. Altogether,
these data contribute to the assumption that ER-positive ILC
and IDC respond differently to chemotherapy.
Table 2 Percentage of estrogen receptor (ER) expression in ER-positive invasive lobular (ILC) or invasive ductal (IDC) breast cancer
Characteristic ILC (n = 4498) ER expression group (%) IDC (n = 21,667) ER expression group (%) P value
10–69% 70–89% C90% 10–69% 70–89% C90%
Age at diagnosis (years)
\50 51 (8) 113 (17) 507 (75) 443 (11) 616 (15) 2952 (74) 0.0227
50–69 121 (5) 268 (11) 2116 (84) 571 (5) 991 (8) 10,705 (87) \.0001
C70 39 (3) 121 (9) 1162 (88) 184 (3) 320 (6) 4887 (91) 0.0001
Tumor size (cm)
\1 26 (4) 83 (12) 578 (84) 221 (4) 393 (8) 4537 (88) 0.0003
1–2 81 (5) 169 (10) 1456 (85) 521 (5) 880 (8) 8975 (87) 0.144
[2 99 (5) 247 (12) 1696 (83) 445 (8) 637 (11) 4858 (81) \.0001
Axillary nodal status
Negative 132 (5) 301 (11) 2401 (84) 709 (5) 1168 (8) 12,444 (87) \.0001
Positive 76 (5) 195 (12) 1321 (83) 480 (7) 738 (10) 5783 (83) 0.002
Grade
1 33 (4) 73 (9) 665 (87) 170 (3) 439 (7) 5732 (90) 0.001
2 145 (5) 338 (11) 2633 (84) 418 (4) 828 (8) 8597 (88) \.0001
3 21 (5) 57 (14) 336 (81) 581 (12) 613 (13) 3689 (75) 0.0001
HER2 status
Negative 183 (4) 469 (11) 3589 (85) 798 (4) 1532 (8) 16,774 (88) \.0001
Positive 24 (13) 28 (15) 131 (72) 392 (17) 378 (17) 1457 (66) 0.199
Table 3 Percentage of progesterone receptor (PR) expression in PR-positive invasive lobular (ILC) or invasive ductal (IDC) breast cancer
Characteristic ILC (n = 3561) PR expression group (%) IDC (n = 17,790) PR expression group (%) P value
10–69% 70–89% C90% 10–69% 70–89% C90%
Age at diagnosis (years)
\50 117 (18) 122 (19) 407 (63) 823 (23) 681 (19) 2041 (58) 0.010
50–69 615 (32) 339 (17) 989 (51) 3079 (31) 1816 (18) 4978 (50) 0.611
C70 318 (33) 180 (19) 474 (49) 1268 (29) 761 (17) 2343 (54) 0.021
Tumor size (cm)
\1 136 (26) 96 (18) 296 (56) 1164 (27) 740 (17) 2335 (55) 0.698
1–2 390 (28) 248 (18) 737 (54) 2371 (27) 1600 (19) 4666 (54) 0.759
[2 508 (32) 286 (18) 817 (51) 1596 (34) 896 (19) 2270 (48) 0.107
Axillary nodal status
Negative 641 (29) 402 (18) 1171 (53) 3265 (28) 2125 (18) 6375 (54) 0.461
Positive 391 (30) 234 (18) 668 (52) 1831 (32) 1075 (19) 2836 (49) 0.329
Grade
1 168 (28) 107 (18) 332 (55) 1295 (24) 975 (18) 3216 (59) 0.073
2 729 (30) 439 (18) 1300 (53) 2306 (28) 1496 (18) 4369 (53) 0.436
3 108 (32) 56 (17) 172 (51) 1423 (39) 713 (20) 1510 (41) 0.002
HER2 status
Negative 984 (29) 610 (18) 1790 (53) 4390 (27) 2933 (18) 8677 (54) 0.151
Positive 47 (38) 19 (15) 57 (46) 702 (46) 288 (19) 524 (35) 0.033
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Concerning the response of ILC and IDC to adjuvant
hormonal treatment of breast cancer, a study by Rakha
et al. showed that the response was better in patients with
ILC and that they had a better survival as compared to
matched patients with IDC [13]. A more recent study by
van de Water et al. showed a similar effect of endocrine
therapy regimens in IDC and ILC. On the other hand, they
also reported that patients with ER-rich tumors experienced
a larger benefit of upfront Exemestane, while patients with
ER-poor tumors had better outcomes with sequential
therapy, irrespective of histological subtype [14]. This
finding emphasizes the relevance of quantification of ER
expression levels in hormonal treatment strategies. In
concordance with our study, van de Water et al. observed
no significant differences between ILC and IDC when
looking at semi-quantitative ER expression levels.
Furthermore, studies investigating progesterone as a pre-
dictive marker for response to endocrine therapy show that
loss of PR expression predicts relative resistance to
tamoxifen, whereas maintenance of response to aromatase
inhibitors can be observed, suggesting a selective role of
this treatment in this subgroup [15–17].
In the current era of molecular characterization of breast
cancer, most patients with ILC should be classified as
luminal A, since ILC is high in ER and PR expression,
often low grade and most often HER2-negative [16]. In
general, luminal A type tumors do show a good respon-
siveness to hormonal therapy and because of this, tamox-
ifen and aromatase inhibitors serve as keystone therapies in
ER/PR-positive ILC. This makes it difficult to prove if the
good prognosis of patients with lobular breast cancer
treated with endocrine therapy, and the apparent lack of an
Fig. 1 Percentage of estrogen
receptor (ER) expression in ER-
positive invasive lobular (ILC)
or invasive ductal (IDC) breast
cancer
Fig. 2 Percentage of
progesterone receptor (PR)
expression in PR-positive
invasive lobular (ILC) or
invasive ductal (IDC) breast
cancer
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additional effect of chemotherapy, is the result of an
excellent response to endocrine treatment or of a reduced
chemo-sensitivity. In this light, the recent St Gallen
guideline also stated that it is among these patients with the
‘luminal’ type of breast cancer, of which ILC is typical
example, that uncertainty exists whether to use adjuvant
chemotherapy [3].
Some limitations in this study should be considered
when interpreting its results. Despite the fact that these data
are derived from a large prospectively collected dataset,
some missing values were observed with respect to tumor
size, axillary nodal status, grade, HER2 status, and ER
expression. However, the number of missing values is too
small to have a real and relevant impact on the results.
Moreover, information on other tumor characteristics, such
as lymphovascular invasion was not available in this
database.
In conclusion, our study provides strong evidence that,
when looking at patients with ER and PR-positive breast
cancer, ILC and IDC do not differ with respect to quanti-
tative ER and PR expression levels. This finding provides
additional proof for the lower chemo-sensitivity of ILC and
the opinion that histological subtype should play an
important role in the decision-making process regarding
the use of chemotherapy in this patient subgroup. Future
(neo)adjuvant randomized studies or analyses of existing
trial data are warranted to provide further evidence on this
subject.
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